Can Medicinal Cannabis Help Kids’ Autism, ADHD or Tourette’s? Here’s What We Know so Far

Why It Matters

With families seeking alternatives to conventional psychotropics, the lack of solid efficacy data and safety uncertainties pose significant clinical and regulatory challenges for the paediatric market.

Key Takeaways

• Medicinal cannabis prescriptions for children have surged in Australia.
• Evidence shows mixed or no benefit for autism, ADHD, Tourette’s.
• Most products are unapproved and not subsidised, making them costly.
• CBD is preferred over THC due to fewer side‑effects.
• Ongoing clinical trials aim to clarify efficacy and safety.

Pulse Analysis

The surge in paediatric medicinal cannabis prescriptions reflects a broader shift toward cannabis‑derived therapies in Australia’s healthcare system. Regulatory bodies such as the TGA have begun to accommodate off‑label use, yet most products remain unapproved, lacking formal safety and quality assessments. This regulatory gray area, combined with the high out‑of‑pocket costs for families, underscores the tension between patient demand and evidence‑based practice, especially as traditional medications for autism, ADHD and Tourette’s carry notable side‑effect burdens.

Scientific scrutiny of cannabis for behavioural and emotional disorders remains limited. The largest controlled trial involving 150 youths with autism produced inconclusive outcomes, showing occasional reductions in disruptive behaviour but no statistically significant advantage over placebo. THC, the psychoactive component, is generally avoided in children due to risks of paranoia and psychosis, while cannabidiol (CBD) is favoured for its milder side‑effect profile, which can include stomach upset and drowsiness. Moreover, CBD’s potential to interact with sedatives and anti‑seizure drugs adds a layer of clinical complexity, highlighting the need for cautious, physician‑guided use.

Looking ahead, several multinational clinical trials are recruiting participants to evaluate standardized CBD formulations for autism and ADHD, promising more rigorous data on efficacy, dosing, and long‑term safety. Until these results emerge, clinicians are advised to discuss the limited evidence base, cost considerations, and regulatory status with families. Policymakers may also need to address the subsidy gap and develop clearer guidelines to ensure that any future adoption of medicinal cannabis for children aligns with robust scientific standards and patient safety.